To evaluate the Safety and efficacy of Unani formulation Itrifal Muqawwi Dimagh in NisyÄ?n (Amnesia)

Clinical Validation of a Unani Pharmacopoeial formulation Itrifal Muqawwi Dimagh in NisyÄ?n (Amnesia)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2015/12/006430

Enrollment

300

Registered

2015-12-08

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- NisyÄ?n (Amnesia) Health Condition 2: R413- Other amnesia

Interventions

Intervention1: Itrifal Muqawwi Dimagh: 5 g twice daily Orally, to be taken with water in morning and at bedtime for twelve weeks Control Intervention1: nil: nil

Eligibility

Inclusion criteria

Inclusion criteria: The patients fulfilling the following criteria will be included in this study: • Patients of either sex in the age group 40-65 years. • Patients of NisyÄ?n (Amnesia) having: ï?§ Subjective complaints of memory problems ï?§ MMSE score of 10-24 representing mild to moderate cognitive impairment

Exclusion criteria

Exclusion criteria: The patients having any of the following criteria will be excluded from the study: 1. Clinical presentation and/or history of any organic neurological disease which interferes with the function of limbic system. 2. Known cases of hypothyroidism or hyperthyroidism. 3. Vitamin B12 deficiency 4. Patients on Psychotropic Drugs 5. Clinical presentation and/or history of a chronic disease that requires long-term treatment, e.g., DM, tuberculosis, HIV infection, syphilis, CVD, pulmonary disease, CKD, chronic liver disease, or any other serious and/or unstable medical condition that, in the opinion of the investigator, could expose the patients to undue risk of a significant adverse event or interfere with assessment of safety or efficacy during the course of the trial. 6. Pregnant and lactating women 7. H/o Addiction (alcohol, drugs) 8. H/o Hypersensitivity to the study drug or any of its ingredients

Design outcomes

Primary

Measure	Time frame
Outcome TimePoints improvement in the sign and symptoms of NisyÄ?n (Amnesia)Timepoint: 12 weeks	—

Secondary

Measure	Time frame
Hematological and biochemical assessments for safetyTimepoint: 12 weeks	—

Countries

India

Contacts

Public ContactDr Pradeep Kumar

Central Council for Research in Unani Medicine (CCRUM)

ccrum507@gmail.com9810161758

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026